European Journal of Radiology
Volume 54, Issue 2 , Pages 264-270 , May 2005

Detectability of liver metastases in malignant melanoma: prospective comparison of magnetic resonance imaging and positron emission tomography

  • Nadir Ghanem

      Affiliations

    • Departments of Diagnostic Radiology, University Hospital Freiburg, Freiburg 79106, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 761 270 3806; fax: +49 761 270 3831.
    • ,
  • Carsten Altehoefer

      Affiliations

    • Departments of Diagnostic Radiology, University Hospital Freiburg, Freiburg 79106, Germany
    • ,
  • Stefan Högerle

      Affiliations

    • Departments of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
    • ,
  • Egbert Nitzsche

      Affiliations

    • Departments of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
    • ,
  • Christian Lohrmann

      Affiliations

    • Departments of Diagnostic Radiology, University Hospital Freiburg, Freiburg 79106, Germany
    • ,
  • Oliver Schäfer

      Affiliations

    • Departments of Diagnostic Radiology, University Hospital Freiburg, Freiburg 79106, Germany
    • ,
  • Elmar Kotter

      Affiliations

    • Departments of Diagnostic Radiology, University Hospital Freiburg, Freiburg 79106, Germany
    • ,
  • Mathias Langer

      Affiliations

    • Departments of Diagnostic Radiology, University Hospital Freiburg, Freiburg 79106, Germany

Received 7 April 2004 ,Revised 2 July 2004 ,Accepted 7 July 2004.

References 

  1. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J. Am. Acad. Dermatol. 1996;34:839–847
  2. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Ang KK. Cutaneous melanoma. Philadelphia (New York): Lippincott-Raven; 1997;
  3. Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma. Cancer. 1998;83:1664–1678
  4. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J. Clin. Oncol. 1983;1:126–134
  5. Lee YT. Malignant melanoma: pattern of metastasis. CA Cancer J. Clin. 1980;30:137–142
  6. Lehnert T, Golling M. Indication and results of liver resection for metastatic disease. Radiologe. 2001;41:40–48
  7. Böni R, Huch Böni RA, Steinert H, Burg G, Buck A, Marincek B, et al. Staging of malignant melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br. J. Dermatol. 1995;132:556–562
  8. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Research. 1996;6:325–329
  9. Eigtved A, Andersson AP, Dahlstrom K, Rabol A, Jensen M, Holm S, et al. Use of fluorine-18 fluorodeosyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur. J. Nucl. Med. 2000;27:70–75
  10. Holder WD, White RL, Zuger JH, Easton EJ, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann. Surg. 1998;227:764–769
  11. Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J. Clin. Oncol. 1998;16:1770–1776
  12. Rinne D, Baum RP, Hör G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998;82:1664–1671
  13. Steinert HC, Huch Boni RA, Buck A, Boni R, Berthold T, Marincek B, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;195:705–709
  14. Sica GT, Ji H, Ros PR. CT and MR imaging of hepatic metastases. Am. J. Roentgenol. 2000;174:691–698
  15. Fröhlich A, Diederichs CG, Staib L, Vogel J, Beger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDG PET. J. Nucl. Med. 1999;40:250–255
  16. Kanematsu M, Hoshi H, Itoh K, Murakami T, Hori M, Kondo H, et al. Focal hepatic lesion detection: comparison of four fat-suppressed T2-weighted MR imaging pulse sequences. Radiology. 1999;211:363–371
  17. Premkumar A, Sanders L, Marincola F, Feuerstein I, Concepcion R, Schwartzentruber D. Visceral metastases from melanoma: findings on MR imaging. Am. J. Roentgenol. 1992;158:293–298
  18. Semelka R, Helmberger TKG. Contrast agents for MR imaging of the liver. Radiology. 2001;218:27–38
  19. Blake SP, Weisinger K, Atkins MB, Raptopoulos V. Liver metastases from melanoma: detection with multiphasic contrast-enhanced CT. Radiology. 1999;213:92–96
  20. Krug B, Dietlein M, Groth W, Stutzer H, Psaras T, Gossmann A, et al. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. Acta Radiol. 2000;41:446–452
  21. Wiesner W, Engel H, von Schulthess GK, Krestin GP, Bicik I. FDG PET-negative liver metastases of a malignant melanoma and FDG PET-positive hurthle cell tumor of the thyroid. Eur. Radiol. 1999;9:975–978
  22. Yang M, Martin DR, Karabulut N, Frick MP. Comparison of MR and PET imaging for the evaluation of liver metastases. J. Magn. Reson. Imaging. 2003;17:343–349
  23. Wong C, Silverman DH, Seltzer M, et al. The impact of 2-Deoxy-2 [18F] Fluoro-D-Glucose whole body positron emission tomography for managing patients with melanoma: the referring physician s perspective. Mol. Imaging Biol. 2002;4:185–190
  24. Prichard RS, Hill AD, Shekan SJ, O Higgins NJ (2002). Positron emission tomography for staging and management of malignant melanoma. Br J Surg 89, 389–96.

PII: S0720-048X(04)00247-5

doi: 10.1016/j.ejrad.2004.07.005

European Journal of Radiology
Volume 54, Issue 2 , Pages 264-270 , May 2005

Article Tools

* Image Usage & Resolution